Drug Resistance in Ovarian Cancer
Author Information
Author(s): Kolfschoten G M, Hulscher T M, Pinedo H M, Boven E
Primary Institution: Department of Medical Oncology, University Hospital Vrije Universiteit
Hypothesis
Can drug resistance features and S-phase fraction predict drug response in ovarian cancer xenografts?
Conclusion
The study found that LRP mRNA and the S-phase fraction are the best predictors for drug response in ovarian cancer, particularly for cisplatin.
Supporting Evidence
- The response rate to cisplatin, cyclophosphamide, and doxorubicin in the xenografts resembled results from phase II trials.
- None of the 15 ovarian cancer xenografts showed detectable MDR 1 expression.
- LRP and MRP 1 expression levels were low to moderate.
- There was a weak inverse relationship between LRP expression and sensitivity to cisplatin and cyclophosphamide.
- The S-phase fraction showed a relation with sensitivity to cisplatin.
Takeaway
Researchers looked at how certain factors affect how well ovarian cancer treatments work, and they found that two specific factors can help predict treatment success.
Methodology
The study investigated 15 human ovarian cancer xenografts, measuring drug response and expression levels of various resistance markers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website